[Featured Stock] DND Pharmatech Completes Phase 2 Clinical Trial Dosing for Nonalcoholic Steatohepatitis Treatment... 'Strong Performance'

DND Pharmatech is showing strong performance. The news of completing clinical dosing for its nonalcoholic steatohepatitis treatment appears to have had an impact.

As of 10:46 AM on the 18th, DND Pharmatech was trading at 59,000 KRW, up 8,000 KRW (15.69%) from the previous trading day.

On this day, DND Pharmatech announced that its metabolic disorder-related nonalcoholic steatohepatitis (MASH) treatment 'DD01', currently in clinical development in the United States, successfully completed dosing at 12 weeks for all patients in the Phase 2 clinical trial. The company has begun analyzing key data, including the primary endpoint MRI-PDFF. The results of the primary endpoint are expected to be announced by June.

DD01 is a long-acting dual agonist developed by DND Pharmatech that simultaneously targets GLP-1 and glucagon receptors. In the Phase 1 clinical trial conducted in the U.S., a 4-week dosing in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) accompanied by obesity and type 2 diabetes showed an average 52.2% reduction in liver fat in the high-dose group.

The subsequent Phase 2 trial was designed as a randomized, double-blind, placebo-controlled study involving 67 overweight and obese patients with a body mass index (BMI) of 25 kg/㎡ or higher, who have metabolic dysfunction-associated steatohepatitis (MASLD·MASH), conducted at approximately 12 clinical trial sites in the U.S.

During the total 48-week dosing period, the primary endpoint is evaluated at 12 weeks using MRI-PDFF to measure the 'proportion of patients with a liver fat reduction of 30% or more.' At 48 weeks, liver biopsy will be used to confirm resolution of MASH and improvement in fibrosis, aiming to secure key data for U.S. Food and Drug Administration (FDA) approval.

Based on the data related to the 12-week primary endpoint, the company plans to actively pursue strategic partnerships with global pharmaceutical companies. The company explained that preliminary discussions are currently underway with multiple global firms.